Brokers Issue Forecasts for Abeona Therapeutics Inc’s Q3 2019 Earnings (ABEO)

Abeona Therapeutics Inc (NASDAQ:ABEO) – Equities researchers at Jefferies Financial Group issued their Q3 2019 EPS estimates for Abeona Therapeutics in a report issued on Wednesday, March 20th, Zacks Investment Research reports. Jefferies Financial Group analyst M. Raycroft expects that the biopharmaceutical company will post earnings of ($0.38) per share for the quarter. Jefferies Financial Group also issued estimates for Abeona Therapeutics’ Q4 2019 earnings at ($0.48) EPS.

ABEO has been the subject of several other research reports. BidaskClub lowered shares of Abeona Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, December 22nd. Cantor Fitzgerald set a $29.00 price target on shares of Abeona Therapeutics and gave the company a “buy” rating in a report on Tuesday, March 19th. Zacks Investment Research raised shares of Abeona Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, February 6th. ValuEngine raised shares of Abeona Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, March 5th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $30.00 price objective on shares of Abeona Therapeutics in a report on Thursday, February 21st. One analyst has rated the stock with a sell rating, two have given a hold rating and eight have assigned a buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $26.00.

Shares of ABEO stock traded down $0.01 during trading hours on Friday, hitting $7.68. 294,466 shares of the company were exchanged, compared to its average volume of 381,392. Abeona Therapeutics has a 52-week low of $6.26 and a 52-week high of $22.00. The firm has a market cap of $368.74 million, a P/E ratio of -6.45 and a beta of 1.94.

A number of large investors have recently modified their holdings of the stock. Parkside Advisors LLC raised its position in Abeona Therapeutics by 16.0% in the 4th quarter. Parkside Advisors LLC now owns 14,530 shares of the biopharmaceutical company’s stock worth $104,000 after purchasing an additional 2,000 shares during the period. SG Americas Securities LLC raised its position in Abeona Therapeutics by 23.7% in the 4th quarter. SG Americas Securities LLC now owns 22,720 shares of the biopharmaceutical company’s stock worth $162,000 after purchasing an additional 4,351 shares during the period. Geode Capital Management LLC increased its position in shares of Abeona Therapeutics by 2.0% in the fourth quarter. Geode Capital Management LLC now owns 341,206 shares of the biopharmaceutical company’s stock valued at $2,436,000 after acquiring an additional 6,826 shares during the period. Metropolitan Life Insurance Co. NY increased its position in shares of Abeona Therapeutics by 247.2% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 10,194 shares of the biopharmaceutical company’s stock valued at $73,000 after acquiring an additional 7,258 shares during the period. Finally, Allianz Asset Management GmbH increased its position in shares of Abeona Therapeutics by 9.4% in the third quarter. Allianz Asset Management GmbH now owns 110,649 shares of the biopharmaceutical company’s stock valued at $1,416,000 after acquiring an additional 9,465 shares during the period. Institutional investors own 67.91% of the company’s stock.

In other Abeona Therapeutics news, Director Stephen B. Howell bought 4,000 shares of the firm’s stock in a transaction that occurred on Monday, April 8th. The shares were bought at an average price of $7.77 per share, for a total transaction of $31,080.00. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Stefano Buono bought 70,000 shares of the firm’s stock in a transaction that occurred on Thursday, April 11th. The stock was acquired at an average price of $7.80 per share, for a total transaction of $546,000.00. Following the transaction, the director now owns 20,980 shares in the company, valued at $163,644. The disclosure for this purchase can be found here. 6.70% of the stock is owned by company insiders.

About Abeona Therapeutics

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.

Further Reading: Quiet Period

Get a free copy of the Zacks research report on Abeona Therapeutics (ABEO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Abeona Therapeutics (NASDAQ:ABEO)

Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.